ArticleBosnian journal of basic medical sciences2010
Lipoprotein (a) as an acute phase reactant in patients on chronic hemodialysis.
Article in Bosnian journal of basic medical sciences, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 14 citations in OpenAlex.
- Lipoprotein(a) during COVID-19 hospitalization: Thrombosis, inflammation, and mortality.Atherosclerosis · 2022Article
- Serum concentrations of small dense low-density lipoprotein cholesterol and lipoprotein(a) are related to coronary arteriostenosis in Takayasu arteritis.Journal of clinical laboratory analysis · 2021Article
- Lipoprotein(a) and Cardiovascular Disease Prevention across Diverse Populations.Cardiology and therapy · 2020Review
- Lipoprotein(a) and Its Potential Association with Thrombosis and Inflammation in COVID-19: a Testable Hypothesis.Current atherosclerosis reports · 2020Review
- Serum lipoprotein (a) and atherosclerotic changes in hemodialysis patients.Journal of renal injury prevention · 2013Article
- A Systematic Literature Review of the Association of Lipoprotein(a) and Autoimmune Diseases and Atherosclerosis.International journal of rheumatology · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lipoprotein (a) [Lp(a)], is an independent risk factor for atherosclerotic cardiovascular disease in patients on chronic hemodialysis. A low concentration of high density lipoprotein cholesterol (HDL-C) and serum albumin are another potential risk factors. The purpose of this study was to explore in patients on chronic hemodialysis, whether Lp(a) elevated levels are influenced by activated acute phase response (APR) and the correlation of Lp(a) with HDL-C and serum albumin. In 69 hemodialysis patients with C-reactive protein (CRP) levels over than 10 mg/L and 101 hemodialysis patients with CRP levels in the normal range, Lp(a), HDL-C and serum albumin were determined in relation to CRP, as a sensitive marker of an APR. Results showed that serum concentration of CRP in 69 hemodialysis patients was significantly higher than in controls (44,62 mg/L versus 8,75 mg/L, p<0,01).Patients with elevated CRP had significantly higher serum levels of Lp(a) and lower serum levels of HDL-C and albumin, than patients with CRP in the normal range ( 35,39 mg/dl versus 28,6 mg/dl, p<0,01, 0,91 mmol/L versus 1,29 mmol/L, p<0,01 and 33,56 g/L versus 35,86 g/L, p<0,01). Lp(a) levels correlated positively with CRP and negatively with HDL-C and serum albumin, in patients with elevated CRP, but not in healthy controls. According to the results Lp(a) reacts as an acute phase protein, in patients with APR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.